Olaparib monotherapy (mCRPC, HRR-mutant)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Components	`DRUG-OLAPARIB`

ID	`REG-OLAPARIB-MONO`
Type	Regimen
Status	pending_clinical_signoff
Diseases	None declared
Sources	`SRC-ESMO-PROSTATE-2024` `SRC-NCCN-PROSTATE-2025`

Notes

PROfound: olaparib superior to enzalutamide / abiraterone in HRR-mutant mCRPC post-ARPI. BRCA1/2 cohort largest benefit. Requires germline +/- somatic HRR testing pre-start.

Used By

Handbook Chapters

HB-OVARIAN-MAINTENANCE-1L - Advanced ovarian cancer: HRD/BRCA first-line maintenance reasoning
HB-PROSTATE-MCRPC-1L - Metastatic castration-resistant prostate cancer: biomarker and sequencing reasoning

Handbook Questions

HQ-PROSTATE-MCRPC-1L-002 - HQ-PROSTATE-MCRPC-1L-002

Indication

IND-PROSTATE-MCRPC-1L-PARPI - IND-PROSTATE-MCRPC-1L-PARPI
IND-PROSTATE-MCRPC-2L-PARPI - IND-PROSTATE-MCRPC-2L-PARPI